

KERYX BIOPHARMACEUTICALS INC  
Form 8-K  
May 06, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **May 5, 2005**

**Keryx Biopharmaceuticals, Inc.**  
(Exact Name of Registrant as Specified in Charter)

<b>Delaware</b>	<b>000-30929</b>	<b>13-4087132</b>
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**750 Lexington Avenue  
New York, New York 10022**  
(Address of Principal Executive Offices)

**(212) 531-5965**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  - Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
-

**Item 8.01. Other Events**

On May 5, 2005, Keryx Biopharmaceuticals, Inc. issued a press release announcing interim results from a Phase II clinical study for KRX-101 (Sulodexide Gelcaps) for the treatment of diabetic nephropathy. The data was presented by Dr. Edmund J. Lewis, MD, on May 5, 2005, at the National Kidney Foundation Spring Clinical Meeting in Washington, D.C. A copy of such press release is being filed as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits**

(c) Exhibits

The following exhibit is filed as a part of this report:

**Exhibit**

**Number Description**

99.1 Press Release dated May 5, 2005

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Keryx Biopharmaceuticals, Inc.**

(Registrant)

Date: May 5, 2005

By: /s/ Ron Bentsur

Ron Bentsur

Vice President, Finance and Investor Relations

---

**INDEX TO EXHIBITS**

**Exhibit**

**Number Description**

99.1 Press Release dated May 5, 2005